Tracker › Companies › Boundless Bio, Inc.
4 No sign of it. We found no public evidence tying Boundless Bio, Inc.'s cuts to AI.
Every tracked 2026 layoff at Boundless Bio, Inc., newest first. Scores are 0–100: how strongly the public evidence ties the cuts to AI. Sources are linked on each one.
AI score 4/100 (Minimal) · 80% interval 4–5 · evidence grade D · US · Pharma / Chemicals
Stated reason: On June 23, 2026, Boundless Bio, in connection with signing of the Merger Agreement, announced a workforce reduction of approximately 75% of Boundless Bio’s workforce. Boundless Bio expects to incur one-time costs of approximately $3.0 million to $5.0 million in connection with the workforce reduction primarily related to one-time termination benefits (some of which are contractual), including severance and healthcar…
Why 4: Merger / acquisition integration · Drivers: industry AI exposure +0.5, contrary evidence −0.2
Evidence: SEC filing. Signals: attribution 0.0, primary source 0.0, exec statement 0.0, role exposure 0.653, industry exposure 0.712, AI investment 0.0, contrary evidence 0.15 · typical Health Care & Pharma roles (no roles named)
Headcount basis: not disclosed
Scores are evidence-based estimates from a published model, not findings that AI caused any layoff. Spot something wrong or missing? Tell us.
Other Health Care & Pharma layoffs we track.
Health Care & Pharma · 738 workers
Health Care & Pharma · 322 workers
Health Care & Pharma · 250 workers
Health Care & Pharma · 108 workers
Health Care & Pharma · 85 workers
Health Care & Pharma
